Last checked at 
LONDON (Alliance News) - AstraZeneca PLC Tuesday said it has provided an update on its immuno-oncology pipeline, including positive data on its MEDI4736 treatment, at the American Society Of Clinical Oncology in Chicago.
This included data on its compound MEDI4736 as a monotherapy, and in combination with tremelimumab.
Data on MEDI4736 as a monotherapy in heavily pre-treated patients with non-small cell lung cancer is "encouraging", AstraZeneca said, and suggest that patients with PD-L1 positive tumours may have an improved overall response rate compared to PD-L1 negative tumours which highlights the unmet medical need for the majority of tumours that are PD-L1 negative.
The combination of MEDI4736 and tremelimumab is demonstrating efficacy regardless of PD-L1 status, AstraZeneca said, and also a manageable safety profile with a discontinuation rate due to related adverse effects of only 7%.
"The data presented on the combination of MEDI4736 and tremelimumab are truly exciting. As the frontrunner combination of two immuno-oncology molecules in non-small cell lung cancer, it is demonstrating promising clinical activity, in particular in the majority of patients who have low or no PD-L1 expression," said Chief Executive Officer Pascal Soriot in a statement.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
